News | October 21, 2009

First Trial Implants Made With New GORE TAG Thoracic Endoprosthesis

October 21, 2009 – W. L. Gore and Associates today announced the first human implants of the next generation Conformable GORE TAG Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms (TAAs).

The first implants were performed by Joshua Rovin, M.D. and Eugene Murphy, M.D., at Bayfront Medical Center and William McMillan, M.D. and Scott Schultz, M.D., at North Memorial Medical Center. The devices were used to treat patients with a TAA, which is an enlargement that develops in weakened areas in the thoracic aorta.

Gore received approval of an investigational device exemption (IDE) from the FDA to investigate the use of the next generation Conformable GORE TAG Thoracic Endoprosthesis in TAAs. William Jordan, MD, from the University of Alabama, Birmingham, will serve as the national principle investigator in the Conformable GORE TAG Device in Thoracic Aortic Aneurysm Trial (Gore TAG 08-03). “This study will evaluate device performance across the wide portfolio of sizes available with the next generation Conformable GORE TAG Device,” Dr. Jordan said. The next generation device portfolio includes device diameters ranging from 21–45 mm, as well as tapered devices, and the study will investigate the treatment of patients with aortic diameters of 16–42 mm.

The commercially available GORE TAG Thoracic Endoprosthesis provides a minimally invasive option for safely and effectively treating patients with aneurysms of the descending thoracic aorta (DTA). It is comprised of an ePTFE graft with an outer self-expanding nitinol support structure to combine both device flexibility and material durability. It received pre-market approval from the FDA in 2005.

In addition to TAAs, the next generation Conformable GORE TAG Device has been approved to investigate endovascular repair of other etiologies including traumatic aortic transection and aortic dissection. Design enhancements include a modified stent frame, repositioned gold bands, and optimized graft material.

For more information: www.goremedical.com


Related Content

News | Stent Grafts

April 26, 2023 — Medtronic today announced its Endurant abdominal aortic aneurysm (AAA) stent graft system continues to ...

Home April 26, 2023
Home
News | Stent Grafts

January 12, 2023 — Medtronic announced the first patient enrollment in the ADVANCE Trial, a head-to-head randomized ...

Home January 12, 2023
Home
News | Stent Grafts
May 4, 2022 – Seeking to bolster its development of a biocompatible graft that promises to reshape the future of cardiac ...
Home May 04, 2022
Home
News | Stent Grafts

October 9, 2019 — Medtronic plc announced it has received Breakthrough Device designation from the U.S. Food and Drug ...

Home October 09, 2019
Home
News | Stent Grafts

October 8, 2019 — PQ Bypass Inc. announced it has received full approval of its investigational device exemption (IDE) ...

Home October 08, 2019
Home
News | Stent Grafts

July 10, 2019 — W. L. Gore & Associates Inc. (Gore) announced the first U.S. implant of the Gore Tag Conformable ...

Home July 10, 2019
Home
Technology | Stent Grafts

May 15, 2019 — W. L. Gore & Associates Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) has granted ...

Home May 15, 2019
Home
News | Stent Grafts

February 14, 2019 — Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft ...

Home February 14, 2019
Home
Technology | Stent Grafts

February 7, 2019 — Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for the Valiant ...

Home February 07, 2019
Home
News | Stent Grafts

January 7, 2019 — Endologix Inc. announced that in order to ensure optimal outcomes for patients, unrestricted sales and ...

Home January 07, 2019
Home
Subscribe Now